Neuroimaging evidence for structural correlates in adolescents resilient to polysubstance use: A five-year follow-up study.


Journal

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
ISSN: 1873-7862
Titre abrégé: Eur Neuropsychopharmacol
Pays: Netherlands
ID NLM: 9111390

Informations de publication

Date de publication:
08 2021
Historique:
received: 14 01 2020
revised: 26 02 2021
accepted: 01 03 2021
pubmed: 27 3 2021
medline: 12 4 2022
entrez: 26 3 2021
Statut: ppublish

Résumé

Early initiation of polysubstance use (PSU) is a strong predictor of subsequent addiction, however scarce individuals present resilience capacity. This neuroimaging study aimed to investigate structural correlates associated with cessation or reduction of PSU and determine the extent to which brain structural features accounted for this resilient outcome. Participants from a European community-based cohort self-reported their alcohol, tobacco and cannabis use frequency at ages 14, 16 and 19 and had neuroimaging sessions at ages 14 and 19. We included three groups in the study: the resilient-to-PSU participants showed PSU at 16 and/or 14 but no more at 19 (n = 18), the enduring polysubstance users at 19 displayed PSU continuation from 14 or 16 (n = 193) and the controls were abstinent or low drinking participants (n = 460). We conducted between-group comparisons of grey matter volumes on whole brain using voxel-based morphometry and regional fractional anisotropy using tract-based spatial statistics. Random-forests machine-learning approach generated individual-level PSU-behavior predictions based on personality and neuroimaging features. Adolescents resilient to PSU showed significant larger grey matter volumes in the bilateral cingulate gyrus compared with enduring polysubstance users and controls at ages 19 and 14 (p<0.05 corrected) but no difference in fractional anisotropy. The larger cingulate volumes and personality trait "openness to experience" were the best precursors of resilience to PSU. Early in adolescence, a larger cingulate gyrus differentiated adolescents resilient to PSU, and this feature was critical in predicting this outcome. This study encourages further research into the neurobiological bases of resilience to addictive behaviors.

Identifiants

pubmed: 33770525
pii: S0924-977X(21)00157-7
doi: 10.1016/j.euroneuro.2021.03.001
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

11-22

Subventions

Organisme : MRF
ID : MRF_MRF-058-0004-RG-DESRI
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R00465X/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : 93558
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S020306/1
Pays : United Kingdom
Organisme : MRF
ID : MRF_MRF-058-0009-RG-DESR-C0759
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N000390/1
Pays : United Kingdom

Informations de copyright

Copyright © 2021. Published by Elsevier B.V.

Auteurs

Irina Filippi (I)

INSERM U1299 Developmental Trajectories & Psychiatry, Ecole Normale Supérieure Paris-Saclay, Université Paris-Saclay, CNRS, Centre Borelli, Digiteo Labs, Avenue des Sciences, Bâtiment 660 Claude Shannon, Gif-sur-Yvette, France.

André Galinowski (A)

INSERM U1299 Developmental Trajectories & Psychiatry, Ecole Normale Supérieure Paris-Saclay, Université Paris-Saclay, CNRS, Centre Borelli, Digiteo Labs, Avenue des Sciences, Bâtiment 660 Claude Shannon, Gif-sur-Yvette, France.

Hervé Lemaître (H)

INSERM U1299 Developmental Trajectories & Psychiatry, Ecole Normale Supérieure Paris-Saclay, Université Paris-Saclay, CNRS, Centre Borelli, Digiteo Labs, Avenue des Sciences, Bâtiment 660 Claude Shannon, Gif-sur-Yvette, France.

Christian Massot (C)

INSERM U1299 Developmental Trajectories & Psychiatry, Ecole Normale Supérieure Paris-Saclay, Université Paris-Saclay, CNRS, Centre Borelli, Digiteo Labs, Avenue des Sciences, Bâtiment 660 Claude Shannon, Gif-sur-Yvette, France.

Pascal Zille (P)

INSERM U1299 Developmental Trajectories & Psychiatry, Ecole Normale Supérieure Paris-Saclay, Université Paris-Saclay, CNRS, Centre Borelli, Digiteo Labs, Avenue des Sciences, Bâtiment 660 Claude Shannon, Gif-sur-Yvette, France.

Pauline Frère (P)

INSERM U1299 Developmental Trajectories & Psychiatry, Ecole Normale Supérieure Paris-Saclay, Université Paris-Saclay, CNRS, Centre Borelli, Digiteo Labs, Avenue des Sciences, Bâtiment 660 Claude Shannon, Gif-sur-Yvette, France.

Rubén Miranda-Marcos (R)

INSERM U1299 Developmental Trajectories & Psychiatry, Ecole Normale Supérieure Paris-Saclay, Université Paris-Saclay, CNRS, Centre Borelli, Digiteo Labs, Avenue des Sciences, Bâtiment 660 Claude Shannon, Gif-sur-Yvette, France; Hôpitaux de Paris, Department of Psychiatry and Addictology, Paul Brousse Hospital, Villejuif, France.

Christian Trichard (C)

Etablissement Public de Santé Barthélémy Durand, Department of Psychiatry, Étampes, France.

Stella Guldner (S)

Central Institute of Mental Health, Department of Cognitive and Clinical Neuroscience, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Hélène Vulser (H)

INSERM U1299 Developmental Trajectories & Psychiatry, Ecole Normale Supérieure Paris-Saclay, Université Paris-Saclay, CNRS, Centre Borelli, Digiteo Labs, Avenue des Sciences, Bâtiment 660 Claude Shannon, Gif-sur-Yvette, France.

Marie-Laure Paillère-Martinot (ML)

INSERM U1299 Developmental Trajectories & Psychiatry, Ecole Normale Supérieure Paris-Saclay, Université Paris-Saclay, CNRS, Centre Borelli, Digiteo Labs, Avenue des Sciences, Bâtiment 660 Claude Shannon, Gif-sur-Yvette, France.

Erin Burke Quinlan (EB)

MRC Social, Genetic and Developmental Psychiatry Research Centre, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom.

Sylvane Desrivieres (S)

MRC Social, Genetic and Developmental Psychiatry Research Centre, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom.

Penny Gowland (P)

School of Physics and Astronomy, Sir Peter Mansfield Imaging Centre, University of Nottingham, Nottingham, United Kingdom.

Arun Bokde (A)

Trinity College, Discipline of Psychiatry, School of Medicine and Trinity College Institute of Neurosciences, Dublin, Ireland.

Hugh Garavan (H)

Department of Psychiatry, University of Vermont College of Medicine, Burlington, VT, USA.

Andreas Heinz (A)

Department of Psychiatry and Psychotherapy, Charite University Hospital Berlin, Berlin, Germany.

Henrik Walter (H)

Department of Psychiatry and Psychotherapy, Charite University Hospital Berlin, Berlin, Germany.

Laura Daedelow (L)

Department of Psychiatry and Psychotherapy, Charite University Hospital Berlin, Berlin, Germany.

Christian Büchel (C)

Department of Systems Neuroscience, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Uli Bromberg (U)

Department of Systems Neuroscience, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Patricia J Conrod (PJ)

Sainte Justine Hospital, Department of Psychiatry, Montreal University, Montréal, Québec, Canada.

Herta Flor (H)

Central Institute of Mental Health, Department of Cognitive and Clinical Neuroscience, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Tobias Banaschewski (T)

Department of Child and Adolescent Psychiatry and Psychotherapy, Medical Faculty Mannheim, Central Institute for Mental Health, Heidelberg University, Mannheim, Germany.

Frauke Nees (F)

Central Institute of Mental Health, Department of Cognitive and Clinical Neuroscience, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Stefan Heintz (S)

Central Institute of Mental Health, Department of Cognitive and Clinical Neuroscience, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Michael Smolka (M)

Technische Universität Dresden, Department of Psychiatry, Dresden, Germany.

Nora C Vetter (NC)

Technische Universität Dresden, Department of Psychiatry, Dresden, Germany.

Dimitri Papadopoulos-Orfanos (D)

Commissariat a l'Energie Atomique et aux Energies Alternatives Centre de Saclay, Neurospin, Saclay, France.

Robert Whelan (R)

School of Psychology and Global Brain Health Institute, University College Dublin, Dublin, Ireland.

Louise Poustka (L)

Department of Child and Adolescent Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany.

Tomas Paus (T)

University of Toronto, Rotman Research Institute, Toronto, Ontario, Canada.

Gunter Schumann (G)

MRC Social, Genetic and Developmental Psychiatry Research Centre, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom.

Eric Artiges (E)

INSERM U1299 Developmental Trajectories & Psychiatry, Ecole Normale Supérieure Paris-Saclay, Université Paris-Saclay, CNRS, Centre Borelli, Digiteo Labs, Avenue des Sciences, Bâtiment 660 Claude Shannon, Gif-sur-Yvette, France; GH Nord Essonne, Service de Psychiatrie 91G16, Orsay, France.

Jean-Luc Martinot (JL)

INSERM U1299 Developmental Trajectories & Psychiatry, Ecole Normale Supérieure Paris-Saclay, Université Paris-Saclay, CNRS, Centre Borelli, Digiteo Labs, Avenue des Sciences, Bâtiment 660 Claude Shannon, Gif-sur-Yvette, France; Centre de Neuro-Imagerie de Recherche, Institut du Cerveau et de la Moëlle épinière, University Hospital Pitié-Salpêtrière, Paris, France. Electronic address: jean-luc.martinot@inserm.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH